Yahoo
NasdaqCM - Delayed Quote USD

Belite Bio, Inc (BLTE)

193.61 +22.52 (+13.16%)
At close: September 4 at 4:00:01 PM EDT
193.61 0.00 (0.00%)
After hours: September 4 at 7:30:02 PM EDT
Trade BLTE on Coinbase
Chart Range Bar
Loading chart for BLTE
  • Previous Close 171.09
  • Open 172.77
  • Bid 123.12 x 200
  • Ask 222.08 x 200
  • Day's Range 172.77 - 193.88
  • 52 Week Range 64.80 - 200.00
  • Volume 735,495
  • Avg. Volume 188,179
  • Market Cap (intraday) 7.797B
  • Beta (5Y Monthly) -1.24
  • PE Ratio (TTM) --
  • EPS (TTM) -3.10
  • Earnings Date (est.) Nov 9, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 223.89

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

www.belitebio.com

41

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/5/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

BLTE
20.39%
MSCI WORLD (^990100-USD-STRD)
12.56%

1-Year Return

BLTE
197.22%
MSCI WORLD (^990100-USD-STRD)
18.99%

3-Year Return

BLTE
486.70%
MSCI WORLD (^990100-USD-STRD)
67.71%

5-Year Return

BLTE
1,448.88%
MSCI WORLD (^990100-USD-STRD)
0.00%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -26.94M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-25M
-20M
-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

185.00
223.89 Average
193.61 Current
303.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/4/2026
Analyst Canaccord Genuity
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 303

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    6.31B

  • Enterprise Value

    5.82B

  • Trailing P/E

    --

  • Forward P/E

    66.67

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    8.13

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -15.65%

  • Return on Equity (ttm)

    -22.10%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -102.36M

  • Diluted EPS (ttm)

    -3.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

193.61 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: